Celltrion, Inc. Logo

Celltrion, Inc.

A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.

068270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
인천광역시 연수구 아카데미로 23, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celltrion, Inc. is a leading global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapeutics. A pioneer in the biosimilar field, Celltrion launched the world's first monoclonal antibody biosimilar and continues to be a market leader. The company's portfolio includes a range of biosimilars and novel drugs targeting therapeutic areas such as immunology, oncology, hematology, and endocrinology. Celltrion provides comprehensive, end-to-end solutions across the biopharmaceutical value chain, from R&D and clinical trials to production and sales, with a commitment to improving worldwide patient access to high-quality, affordable medicines.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Celltrion, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 724.1 KB
2025-09-17 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 33.3 KB
2025-09-08 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획보고서
Korean 70.7 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.0 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-09-01 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 승인(Part2))
Korean 12.2 KB
2025-09-01 00:00
Major Shareholding Notification
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 31.0 KB

Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.